Available in Brazil
A Phase 3b multicenter, randomized, controlled, double-blind clinical trial was designed
to evaluate the Immunogenicity (non-inferiority), 28 days post-immunization, for each
Dengue and Chikungunya serotypes, as well as the safety, 21 days post-immunization, of
the co-administration of the live attenuated Dengue and Chikungunya vaccines compared to
the separate administration in adults aged 18 to 59 years without prior exposure to
either arbovirus.
2Research sites
900Patients around the world